Evidence mapPaperPMID 35379298Full record

ArticleTrials2022

Development of an information system and mobile application for the care of type 2 diabetes patients at the primary care level for the health sector in Mexico: study protocol for a randomized controlled, open-label trial.

Noël C Barengo, Leticia Manuel Apolinar, Norma A Estrada Cruz, José E Fernández Garate, Roberto A Correa González, Paula A Diaz Valencia, Cecilia Alicia Cinco Gonzalez, José Alberto Gómez Rodriguez, Nelly Cisneros González, SANENT Study Group

Registry-linked trialOpen access · goldAbstract readClinical Trial Protocol
In one paragraph

Article in Trials, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04974333 (Development of an Information Board and Mobile Application for the Care of Type 2 Diabetes at the First Level of Medical Care for the Health Sector in Mexico), which is not on this map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
0.8field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04974333 naunknown statusnot on this map

Development of an Information Board and Mobile Application for the Care of Type 2 Diabetes at the First Level of Medical Care for the Health Sector in Mexico

TypeinterventionalSponsorGeneral Health Council, MexicoRan2021 to 2024Enrolled1,512ConditionsDiabetes Mellitus, Type 2ArmsMobile health application on phone
3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it, 3 citations in OpenAlex.

  1. Selection and reporting of usual care comparators when designing primary care trials of complex health interventions: a systematic review.The British journal of general practice : the journal of the Royal College of General Practitioners · 2025
    Pooled it
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 3 countries.

Noël C BarengoHerbert Wertheim College of Medicine & Robert Stempel College of Public Health, Florida International University, Miami, FL, USA.ORCID http://orcid.org/0000-0003-0660-3091
Leticia Manuel ApolinarUnidad de Investigación Médica en Enfermedades Endocrinas, Instituto Mexicano del Seguro Social, Mexico City, Mexico.
Norma A Estrada CruzConsejo de Salubridad General, Mexico City, Mexico.
José E Fernández GarateConsejo de Salubridad General, Mexico City, Mexico.
Roberto A Correa GonzálezConsejo de Salubridad General, Mexico City, Mexico.
Paula A Diaz ValenciaFacultad de Salud Pública, Universidad de Antioquia, Medellín, Colombia.
Cecilia Alicia Cinco GonzalezConsejo de Salubridad General, Mexico City, Mexico.
José Alberto Gómez RodriguezFacultad de Salud Pública, Universidad de Antioquia, Medellín, Colombia.
Nelly Cisneros GonzálezConsejo de Salubridad General, Mexico City, Mexico. nellycisneros@yahoo.com.
SANENT Study Group
Universidad de Antioquia · COFlorida International University · USMexican Social Security Institute · MXSecretaría de Ciencia, Humanidades, Tecnología e Innovación · MX

Funding

Eli Lilly and Company N/A
6 · The paper itself

Abstract

backgroundProviding optimal care for type 2 diabetes (DM2) patients remains a challenge for all healthcare systems. Patients often encounter various barriers in adhering to self-management programs due to lack of knowledge and understanding of self-care activities, lack of individualized and coordinated care, inconvenient and costly education sessions, and poor patient-provider communication. Mobile technologies such as cell phones/smartphones, handheld tablets, and other wireless devices offer new and exciting opportunities for addressing some of these challenges. The purpose of this study is to compare a diabetes management strategy using an information board and a mobile application versus standard care in patients with uncontrolled DM2.

methodThe SANENT (Sistema de Análisis de Enfermedades No Transmisibles) trial is a primary care-based, prospective, two-arm, randomized controlled, open-label, blinded-endpoint study. We aim to recruit 1440 DM2 patients during a period of 6 months until the requested number of participants has been achieved. The total length of the intervention will be 1 year. Both men and women treated for DM2 with an HbA1c > 8.5% and ≥ 20 years of age are eligible to participate in the study. The primary outcome of the study is improved diabetes control measured by changes in HbA1c in the study participants. HbA1c will be measured at baseline, 3-month, 6-month, 9-month, and 12-month follow-up visits in all participants. The main analysis will be based on the intention-to-treat principle. The primary endpoint of the study will be the change in HbA1C within the groups and the differences between the groups. This will be assessed by a repeated measurement approach based on mixed models which contain both fixed effects and random effects. DISCUSSION: The overall goal of this project is to contribute to the evidence for the use of mobile technology to improve the treatment and regulation of poorly controlled DM2 patients living in Mexico. Our proposed project will show how mobile health technology tools can be used in the treatment of patients with uncontrolled DM2 in primary health care in a Latin American population, and particularly how they could help diabetes patients take better care of themselves.

trial registrationClinicalTrials.gov , US National Institutes of Health NCT04974333 . Prospectively registered on July 13, 2021. Protocol version number 1, dated August 15th, 2021.

Indexed as

Diabetes Mellitus, Type 2Mobile ApplicationsFemaleHumansInformation SystemsMaleMexicoPrimary Health CareProspective StudiesRandomized Controlled Trials as TopicUnited StatesControlmHealthPrimary careTelemedicineTreatment complianceType 2 diabetes

Identifiers

PMID35379298
PMCPMC8981629
OpenAlexW4225781371

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.